awmsg logo



linagliptin/metformin (Jentadueto®)


Reference No. 1681

Publication date:
31/07/2013


Last review date:
30/08/2016

Appraisal information

linagliptin/metformin (Jentadueto®) 2.5 mg/1000 mg film-coated tablet
linagliptin/metformin (Jentadueto®) 2.5 mg/850 mg film-coated tablet


Company: Boehringer Ingelheim Ltd
BNF category: Endocrine system
NMG meeting date: 10/04/2013
AWMSG meeting date: 08/05/2013
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1113
Ministerial ratification: 29/07/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus: • as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin; and • in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download